Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Clinical consequences of BRCA2 hypomorphism

  • Castells-Roca, Laia
  • Gutierrez Enriquez, Sara
  • Bonache Real, Sandra
  • Carrasco López, Estela
  • Aza-Carmona, Miriam
  • Montalban Canudas, Gemma
  • Cruz Zambrano, Cristina
  • Llop Guevara, Alba
  • Serra Elizalde, Violeta
  • Diez Gibert, Orland
  • Balmaña Gelpí, Judith
  • Saura Manich, Cristina
  • Bogliolo, Massimo
Breast cancer; Cancer genetics, Cáncer de mama; Genética del cáncer, Càncer de mama; Genètica del càncer, The tumor suppressor FANCD1/BRCA2 is crucial for DNA homologous recombination repair (HRR). BRCA2 biallelic pathogenic variants result in a severe form of Fanconi anemia (FA) syndrome, whereas monoallelic pathogenic variants cause mainly hereditary breast and ovarian cancer predisposition. For decades, the co-occurrence in trans with a clearly pathogenic variant led to assume that the other allele was benign. However, here we show a patient with biallelic BRCA2 (c.1813dup and c.7796 A > G) diagnosed at age 33 with FA after a hypertoxic reaction to chemotherapy during breast cancer treatment. After DNA damage, patient cells displayed intermediate chromosome fragility, reduced survival, cell cycle defects, and significantly decreased RAD51 foci formation. With a newly developed cell-based flow cytometric assay, we measured single BRCA2 allele contributions to HRR, and found that expression of the missense allele in a BRCA2 KO cellular background partially recovered HRR activity. Our data suggest that a hypomorphic BRCA2 allele retaining 37–54% of normal HRR function can prevent FA clinical phenotype, but not the early onset of breast cancer and severe hypersensitivity to chemotherapy.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Role of Splicing Regulatory Elements and In Silico Tools Usage in the Identification of Deep Intronic Splicing Variants in Hereditary Breast/Ovarian Cancer Genes

  • Moles Fernandez, Alejandro
  • Domènech Vivó, Joanna
  • Tenés Felipe, Anna
  • Balmaña Gelpí, Judith
  • Diez Gibert, Orland
  • Gutierrez Enriquez, Sara
Cancer hereditario de mama y ovario; Pseudoexones; Variantes intrónicas profundas spliceogénicas, Càncer hereditari de mama i d'ovari; Pseudoexons; Variants intròniques profundes spliceogèniques, Hereditary breast ovarian cancer; Pseudoexons; Spliceogenic deep intronic variants, The contribution of deep intronic splice-altering variants to hereditary breast and ovarian cancer (HBOC) is unknown. Current computational in silico tools to predict spliceogenic variants leading to pseudoexons have limited efficiency. We assessed the performance of the SpliceAI tool combined with ESRseq scores to identify spliceogenic deep intronic variants by affecting cryptic sites or splicing regulatory elements (SREs) using literature and experimental datasets. Our results with 233 published deep intronic variants showed that SpliceAI, with a 0.05 threshold, predicts spliceogenic deep intronic variants affecting cryptic splice sites, but is less effective in detecting those affecting SREs. Next, we characterized the SRE profiles using ESRseq, showing that pseudoexons are significantly enriched in SRE-enhancers compared to adjacent intronic regions. Although the combination of SpliceAI with ESRseq scores (considering ∆ESRseq and SRE landscape) showed higher sensitivity, the global performance did not improve because of the higher number of false positives. The combination of both tools was tested in a tumor RNA dataset with 207 intronic variants disrupting splicing, showing a sensitivity of 86%. Following the pipeline, five spliceogenic deep intronic variants were experimentally identified from 33 variants in HBOC genes. Overall, our results provide a framework to detect deep intronic variants disrupting splicing., This research was funded by the Spanish Instituto de Salud Carlos III (ISCIII) funding an initiative of the Spanish Ministry of Economy and Innovation, partially supported by European Regional Development FEDER Funds, grant numbers PI16/01218 and PI19/01303. AM-F contract is supported by the award ERAPERMED2019-215 granted by AECC FC and by ISCIII thorough AES 2019, both within the ERAPerMed framework”. J.D.-V. contract is supported by the Secretariat for Universities and Research of the Ministry of Business and Knowledge of the Government of Catalonia and the European Social Fund.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Evaluation of the association of heterozygous germline variants in NTHL1 with breast cancer predisposition: an international multi-center study of 47,180 subjects

  • Li, Na
  • Zethoven, Magnus
  • McInerny, Simone
  • Devereux, Lisa
  • Huang, Yu-Kuan
  • Thio, Niko
  • Gutierrez Enriquez, Sara
  • Moles Fernandez, Alejandro
  • Diez Gibert, Orland
Càncer de mama; Genètica del càncer; Mutació, Cáncer de mama; Genética del cáncer; Mutación, Breast cancer; Cancer genetics; Mutation, Bi-allelic loss-of-function (LoF) variants in the base excision repair (BER) gene NTHL1 cause a high-risk hereditary multi-tumor syndrome that includes breast cancer, but the contribution of heterozygous variants to hereditary breast cancer is unknown. An analysis of 4985 women with breast cancer, enriched for familial features, and 4786 cancer-free women revealed significant enrichment for NTHL1 LoF variants. Immunohistochemistry confirmed reduced NTHL1 expression in tumors from heterozygous carriers but the NTHL1 bi-allelic loss characteristic mutational signature (SBS 30) was not present. The analysis was extended to 27,421 breast cancer cases and 19,759 controls from 10 international studies revealing 138 cases and 93 controls with a heterozygous LoF variant (OR 1.06, 95% CI: 0.82–1.39) and 316 cases and 179 controls with a missense variant (OR 1.31, 95% CI: 1.09–1.57). Missense variants selected for deleterious features by a number of in silico bioinformatic prediction tools or located within the endonuclease III functional domain showed a stronger association with breast cancer. Somatic sequencing of breast cancers from carriers indicated that the risk associated with NTHL1 appears to operate through haploinsufficiency, consistent with other described low-penetrance breast cancer genes. Data from this very large international multicenter study suggests that heterozygous pathogenic germline coding variants in NTHL1 may be associated with low- to moderate- increased risk of breast cancer.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Decapping protein EDC4 regulates DNA repair and phenocopies BRCA1

  • Hernández Viedma, Gonzalo|||0000-0002-3048-9607
  • Ramírez de Haro, Ma. José|||0000-0003-1417-7731
  • Minguillón Pedreño, Jordi|||0000-0003-2124-8294
  • Quiles, Francisco
  • Ruiz de Garibay, G.
  • Aza-Carmona, Miriam|||0000-0003-4448-9541
  • Bogliolo, Massimo|||0000-0001-8240-7784
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Prados-Carvajal, Rosario
  • Fernández-Rodríguez, Juana
  • García, Nadia
  • López, Adrià
  • Gutiérrez-Enríquez, Sara|||0000-0002-1711-6101
  • Diez, Orland|||0000-0001-7339-0570
  • Benitez, Javier|||0000-0002-0923-7202
  • Salinas, Monica
  • Teule, Alex|||0000-0003-0028-7200
  • Brunet, Joan|||0000-0003-1945-3512
  • Radice, Paolo|||0000-0001-6298-4111
  • Peterlongo, Paolo|||0000-0001-6951-6855
  • Schindler, Detlev
  • Huertas, Pablo
  • Puente, Xose P.
  • Lázaro, Coxi
  • Pujana, Miguel Angel|||0000-0003-3222-4044
  • Surralles, Jordi|||0000-0002-4041-7519
BRCA1 is a tumor suppressor that regulates DNA repair by homologous recombination. Germline mutations in BRCA1 are associated with increased risk of breast and ovarian cancer and BRCA1 deficient tumors are exquisitely sensitive to poly (ADP-ribose) polymerase (PARP) inhibitors. Therefore, uncovering additional components of this DNA repair pathway is of extreme importance for further understanding cancer development and therapeutic vulnerabilities. Here, we identify EDC4, a known component of processing-bodies and regulator of mRNA decapping, as a member of the BRCA1-BRIP1-TOPBP1 complex. EDC4 plays a key role in homologous recombination by stimulating end resection at double-strand breaks. EDC4 deficiency leads to genome instability and hypersensitivity to DNA interstrand cross-linking drugs and PARP inhibitors. Lack-of-function mutations in EDC4 were detected in BRCA1/2-mutation-negative breast cancer cases, suggesting a role in breast cancer susceptibility. Collectively, this study recognizes EDC4 with a dual role in decapping and DNA repair whose inactivation phenocopies BRCA1 deficiency.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A RAD51 assay feasible in routine tumor samples calls inhibitor response beyond BRCA mutation

  • Castroviejo-Bermejo, Marta|||0000-0002-8540-5837
  • Cruz Zambrano, Cristina|||0000-0002-6474-7504
  • Llop Guevara, Alba|||0000-0002-7913-9472
  • Gutiérrez-Enríquez, Sara|||0000-0002-1711-6101
  • Ducy, Mandy
  • Ibrahim, Yasir Hussein
  • Gris-Oliver, Albert|||0000-0003-1802-9541
  • Pellegrino, Benedetta
  • Bruna, Alejandra|||0000-0003-1214-9665
  • Guzmán, Marta|||0000-0002-0924-9887
  • Rodríguez, Olga|||0000-0002-0123-9975
  • Grueso, Judit|||0000-0003-1093-7940
  • Bonache, Sandra|||0000-0002-7395-8143
  • Moles-Fernández, Alejandro|||0000-0003-0252-6084
  • Villacampa Javierre, Guillermo|||0000-0003-4868-6585
  • Viaplana, Cristina|||0000-0001-8904-4330
  • Gómez Pardo, Patricia
  • Vidal, Marc
  • Peg, Vicente|||0000-0002-5203-6166
  • Serres Creixams, Xavier|||0000-0001-8642-467X
  • Dellaire, Graham
  • Simard, Jacques|||0000-0001-6906-3390
  • Nuciforo, Paolo|||0000-0003-1380-0990
  • Rubio, Isabel T.|||0000-0003-0035-0679
  • Dientsmann, Rodrigo
  • Barrett, J. Carl|||0000-0003-4042-9859
  • Caldas, Carlos|||0000-0003-3547-1489
  • Baselga Torres, Josep
  • Saura Manich, Cristina|||0000-0001-8296-5065
  • Cortés Castán, Javier|||0000-0001-7623-1583
  • Déas, Olivier
  • Jonkers, Jos|||0000-0002-9264-9792
  • Masson, Jean-Yves
  • Cairo, Stefano
  • Judde, Jean-Gabriel
  • O'Connor, Mark J.|||0000-0003-1823-625X
  • Diez, Orland|||0000-0001-7339-0570
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • Serra, Violeta|||0000-0001-6620-1065
Poly(-ribose) polymerase () inhibitors (i) are effective in cancers with defective homologous recombination repair (), including 1/2-related cancers. A test to identify additional -deficient tumors will help to extend their use in new indications. We evaluated the activity of the i olaparib in patient-derived tumor xenografts (s) from breast cancer () patients and investigated mechanisms of sensitivity through exome sequencing, 1 promoter methylation analysis, and immunostaining of proteins, including 51 nuclear foci. In an independent panel, the predictive capacity of the 51 score and the homologous recombination deficiency () score were compared. To examine the clinical feasibility of the 51 assay, we scored archival breast tumor samples, including 2-related hereditary cancers. The 51 score was highly discriminative of i sensitivity versus PARPi resistance in s and outperformed the genomic test. In clinical samples, all 2-related tumors were classified as -deficient by the 51 score. The functional biomarker 51 enables the identification of i-sensitive and broadens the population who may benefit from this therapy beyond 1/2-related cancers.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Clinical consequences of BRCA2 hypomorphism

  • Castells Roca, Laia|||0000-0002-4604-9999
  • Gutiérrez-Enríquez, Sara|||0000-0002-1711-6101
  • Bonache, Sandra|||0000-0002-7395-8143
  • Bogliolo, Massimo|||0000-0001-8240-7784
  • Carrasco, Estela|||0000-0003-1964-7675
  • Aza-Carmona, Miriam|||0000-0003-4448-9541
  • Montalban, Gemma|||0000-0002-6958-4759
  • Muñoz-Subirana, N.
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Cruz Zambrano, Cristina|||0000-0002-6474-7504
  • Llop Guevara, Alba|||0000-0002-7913-9472
  • Ramírez de Haro, Ma. José|||0000-0003-1417-7731
  • Saura Manich, Cristina|||0000-0001-8296-5065
  • Lasa, Adriana|||0000-0001-9957-9646
  • Serra, Violeta|||0000-0001-6620-1065
  • Diez, Orland|||0000-0001-7339-0570
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • Surralles, Jordi|||0000-0002-4041-7519
The tumor suppressor FANCD1/BRCA2 is crucial for DNA homologous recombination repair (HRR). BRCA2 biallelic pathogenic variants result in a severe form of Fanconi anemia (FA) syndrome, whereas monoallelic pathogenic variants cause mainly hereditary breast and ovarian cancer predisposition. For decades, the co-occurrence in trans with a clearly pathogenic variant led to assume that the other allele was benign. However, here we show a patient with biallelic BRCA2 (c.1813dup and c.7796 A.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

CAGI, the Critical Assessment of Genome Interpretation, establishes progress and prospects for computational genetic variant interpretation methods

  • Jain, Shantanu
  • Bakolitsa, Constantina|||0000-0002-6980-9831
  • Brenner, Steven E.
  • Radivojac, Predrag
  • Moult, John
  • Repo, Susanna
  • Hoskins, Roger A.
  • Andreoletti, Gaia
  • Barsky, Daniel
  • Chellapan, Ajithavalli
  • Chu, Hoyin
  • Dabbiru, Navya
  • Kollipara, Naveen K.
  • Ly, Melissa
  • Neumann, Andrew J.
  • Pal, Lipika R.
  • Odell, Eric
  • Pandey, Gaurav
  • Peters-Petrulewicz, Robin C.
  • Srinivasan, Rajgopal
  • Yee, Stephen F.
  • Yeleswarapu, Sri Jyothsna
  • Zuhl, Maya
  • Adebali, Ogun
  • Patra, Ayoti
  • Beer, Michael A.
  • Hosur, Raghavendra
  • Peng, Jian
  • Bernard, Brady M.
  • Berry, Michael
  • Dong, Shengcheng
  • Boyle, Alan P.
  • Adhikari, Aashish
  • Chen, Jingqi
  • Hu, Zhiqiang
  • Wang, Robert
  • Wang, Yaqiong
  • Miller, Maximilian
  • Wang, Yanran
  • Bromberg, Yana
  • Turina, Paola
  • Capriotti, Emidio|||0000-0002-2323-0963
  • Han, James J.
  • Ozturk, Kivilcim
  • Carter, Hannah
  • Babbi, Giulia|||0000-0002-9816-4737
  • Bovo, Samuele
  • Di Lena, Pietro
  • Martelli, Pier Luigi|||0000-0002-0274-5669
  • Savojardo, Castrense
  • Casadio, Rita
  • Cline, Melissa S.
  • De Baets, Greet
  • Bonache, Sandra|||0000-0002-7395-8143
  • Diez, Orland|||0000-0001-7339-0570
  • Gutiérrez-Enríquez, Sara|||0000-0002-1711-6101
  • Fernández, Alejandro
  • Montalban, Gemma|||0000-0002-6958-4759
  • Ootes, Lars
  • Özkan, Selen|||0000-0002-7398-1351
  • Padilla Sirera, Natàlia|||0000-0002-7872-2279
  • Riera, Casandra
  • de la Cruz, Xavier|||0000-0002-9738-8472
  • Diekhans, Mark|||0000-0002-0430-0989
  • Huwe, Peter J.
  • Wei, Qiong
  • Xu, Qifang
  • Dunbrack, Roland L.
  • Gotea, Valer|||0000-0001-7857-3309
  • Elnitski, Laura
  • Margolin, Gennady
  • Fariselli, Piero
  • Kulakovskiy, Ivan V.
  • Makeev, V.J.|||0000-0001-9405-9748
  • Penzar, Dmitry D.
  • Vorontsov, Ilya E.
  • Favorov, A.V.
  • Forman, Julia R.
  • Hasenahuer, Marcia
  • Fornasari, Maria S.
  • Parisi, Gustavo|||0000-0001-7444-1624
  • Avsec, Ziga
  • Çelik, Muhammed H.
  • Nguyen, Thi Yen Duong
  • Gagneur, Julien|||0000-0002-8924-8365
  • Shi, Fang-Yuan
  • Edwards, Matthew D.|||0000-0002-3573-0025
  • Guo, Yuchun
  • Tian, Kevin
  • Zeng, Haoyang
  • Gifford, David K.
  • Göke, Jonathan
  • Zaucha, Jan|||0000-0003-3289-4590
  • Gough, Julian
  • Ritchie, Graham R.S.
  • Frankish, Adam|||0000-0002-4333-628X
  • Mudge, Jonathan M.
  • Harrow, Jennifer
  • Young, Erin L.
  • Yu, Yao|||0000-0002-2727-1746
  • Huff, Chad D.
  • Murakami, Katsuhiko
  • Nagai, Yoko
  • Imanishi, Tadashi
  • Mungall, Christopher J.
  • Jacobsen, Julius O.B.
  • Kim, Dongsup
  • Jeong, Chan-Seok
  • Jones, David T.
  • Li, Mulin Jun
  • Guthrie, Violeta Beleva
  • Bhattacharya, Rohit
  • Chen, Yun-Ching
  • Douville, Christopher
  • Fan, Jean
  • Kim, Dewey
  • Masica, David
  • Niknafs, Noushin
  • Sengupta, Sohini
  • Tokheim, Collin
  • Turner, Tychele N.
  • Yeo, Hui Ting Grace|||0000-0002-8920-8208
  • Karchin, Rachel
  • Shin, Sunyoung
  • Welch, Rene
  • Keles, Sunduz
  • Li, Yue
  • Kellis, Manolis
  • Corbi-Verge, Carles
  • Strokach, Alexey V.
  • Kim, Philip M.
  • Klein, Teri E.|||0000-0001-5527-6475
  • Mohan, Rahul
  • Sinnott-Armstrong, Nicholas A.
  • Wainberg, Michael
  • Kundaje, Anshul|||0000-0003-3084-2287
  • Gonzaludo, Nina
  • Mak, A.C.Y.
  • Chhibber, Aparna
  • Lam, Hugo Y.K.
  • Dahary, Dvir|||0000-0002-0974-8037
  • Fishilevich, S.
  • Lancet, Doron
  • Lee, Insuk
  • Bachman, Benjamin
  • Katsonis, Panagiotis
  • Lua, Rhonald C.
  • Wilson, Stephen J.
  • Lichtarge, Olivier
  • Bhat, Rajendra R.
  • Sundaram, Laksshman
  • Viswanath, Vivek
  • Bellazzi, Riccardo
  • Nicora, Nicora
  • Rizzo, Ettore
  • Limongelli, Ivan
  • Mezlini, Aziz M.
  • Chang, Ray
  • Kim, Serra
  • Lai, Carmen
  • O'Connor, Robert
  • Topper, Scott
  • van den Akker, Jeroen
  • Zhou, Alicia Y.
  • Zimmer, Anjali D.
  • Mishne, Gilad
  • Bergquist, Timothy R.
  • Breese, Marcus R.
  • Guerrero, Rafael F.|||0000-0002-8451-3609
  • Jiang, Yuxiang
  • Kiga, Nikki
  • Li, Biao
  • Mort, Matthew
  • Pagel, Kymberleigh A.
  • Pejaver, Vikas
  • Stamboulian, Moses H.
  • Thusberg, Janita
  • Mooney, Sean D.
  • Teerakulkittipong, Nuttinee|||0000-0002-2172-9277
  • Cao, Chen
  • Kundu, Kunal
  • Yin, Yizhou
  • Yu, Chen-Hsin
  • Kleyman, Michael
  • Lin, Chiao-Feng
  • Stackpole, Mary
  • Mount, Stephen M.
  • Eraslan, Gökcen
  • Mueller, Nikola S.
  • Naito, Tatsuhiko
  • Rao, Aliz R.
  • Azaria, Johnathan R.
  • Brodie, Aharon
  • Ofran, Yanay
  • Garg, Aditi
  • Pal, Debnath
  • Hawkins-Hooker, Alex
  • Kenlay, Henry
  • Reid, John
  • Mucaki, Eliseos J.
  • Rogan, Peter K.|||0000-0003-2070-5254
  • Schwarz, Jana M.
  • Searls, David B.
  • Lee, Gyu R.
  • Seok, Chaok
  • Krämer, Andreas
  • Shah, Sohela
  • Huang, ChengLai V.
  • Kirsch, Jack F.
  • Shatsky, Maxim
  • Cao, Yue
  • Chen, Haoran
  • Karimi, Mostafa
  • Moronfoye, Oluwaseyi
  • Sun, Yuanfei
  • Shen, Yang
  • Shigeta, Ron
  • Ford, Colby T.
  • Nodzak, Conor
  • Uppal, Aneeta
  • Shi, Xinghua
  • Joseph, Thomas
  • Kotte, Sujatha
  • Rana, Sadhna
  • Rao, Aditya
  • Saipradeep, Vangala G.
  • Sivadasan, Naveen
  • Sunderam, Uma
  • Stanke, Mario
  • Su, Andrew
  • Adzhubey, Ivan
  • Jordan, Daniel M.
  • Sunyaev, Shamil|||0000-0001-5715-5677
  • Rousseau, Frederic
  • Schymkowitz, Joost
  • Van Durme, Joost
  • Tavtigian, Sean V.
  • Carraro, Marco
  • Giollo, Manuel
  • Tosatto, Silvio|||0000-0003-4525-7793
  • Adato, Orit|||0000-0002-2135-8947
  • Carmel, Liran|||0000-0003-0225-8550
  • Cohen, Noa E.|||0000-0002-4638-5407
  • Fenesh, Tzila
  • Holtzer, Tamar
  • Juven-Gershon, Tamar|||0000-0003-2607-5476
  • Unger, Ron
  • Niroula, Abhishek
  • Olatubosun, Ayodeji
  • Väliaho, Jouni
  • Yang, Yang
  • Vihinen, Mauno
  • Wahl, Mary E.
  • Chang, Billy
  • Chong, Ka C.
  • Hu, Inchi
  • Sun, Rui
  • Wu, William Ka Ke|||0000-0002-5662-5240
  • Xia, Xiaoxuan
  • Zee, Benny C.
  • Wang, Maggie Haitian|||0000-0003-1223-4595
  • Wang, Meng
  • Wu, Chunlei
  • Lu, Yutong
  • Chen, Ken
  • Yang, Yuedong
  • Yates, Christopher M.
  • Kreimer, Anat
  • Yan, Zhongxia
  • Yosef, Nir|||0000-0001-9004-1225
  • Zhao, Huying
  • Wei, Zhipeng
  • Yao, Zhaomin
  • Fengfeng, Zhou
  • Folkman, Lukas|||0000-0002-5811-8875
  • Zhou, Yaoqi
  • Daneshjou, Roxana|||0000-0001-7988-9356
  • Altman, Russ B.
  • Inoue, Fumitaka
  • Ahituv, Nadav
  • Arkin, Adam P.
  • Lovisa, Federica
  • Bonvini, Paolo
  • Bowdin, Sarah
  • Gianni, Stefano
  • Mantuano, Elide
  • Minicozzi, Velia
  • Novak, Leonore
  • Pasquo, Alessandra
  • Pastore, Annalisa|||0000-0002-3047-654X
  • Petrosino, Maria
  • Puglisi, Rita
  • Toto, Angelo
  • Veneziano, Liana
  • Chiaraluce, Roberta
  • Ball, Mad P.
  • Bobe, Jason R.
  • Church, George M.
  • Consalvi, Valerio
  • Cooper, David N.|||0000-0002-8943-8484
  • Buckley, Bethany A.
  • Sheridan, Molly B.
  • Cutting, Garry R.
  • Scaini, Maria Chiara|||0000-0002-9583-3034
  • Cygan, Kamil J.
  • Fredericks, Alger M.
  • Glidden, David T.
  • Neil, Christopher
  • Rhine, Christy L.|||0000-0002-5758-5543
  • Fairbrother, William G.
  • Alontaga, Aileen Y.
  • Fenton, Aron W.
  • Matreyek, Kenneth|||0000-0001-9149-551X
  • Starita, Lea M.
  • Fowler, Douglas M.
  • Löscher, Britt-Sabina
  • Franke, Andre|||0000-0003-1530-5811
  • Adamson, Scott I.
  • Graveley, Brenton R.
  • Gray, Joe W.
  • Malloy, Mary J.
  • Kane, John P.
  • Kousi, Maria
  • Katsanis, Nicholas
  • Schubach, Max
  • Kircher, Martin
  • Mak, Angel C.Y.
  • Tang, Paul L.F.
  • Kwok, Pui-Yan
  • Lathrop, Richard H.
  • Clark, Wyatt T.
  • Yu, Guoying K.
  • LeBowitz, Jonathan H.
  • Benedicenti, Francesco|||0000-0002-9458-0688
  • Bettella, Elisa
  • Bigoni, Stefania
  • Cesca, Federica
  • Mammi, Isabella
  • Marino-Buslje, Cristina|||0000-0002-6564-1920
  • Milani, Donatella
  • Peron, Angela|||0000-0002-1769-6548
  • Polli, Roberta
  • Sartori, Stefano
  • Stanzial, Franco
  • Toldo, Irene
  • Turolla, Licia
  • Aspromonte, Maria Cristina|||0000-0002-4937-6952
  • Bellini, Mariagrazia
  • Leonardi, Emanuela|||0000-0001-8486-8461
  • Liu, Xiaoming|||0000-0001-8285-5528
  • Marshall, Christian
  • McCombie, W. Richard
  • Elefanti, Lisa
  • Menin, Chiara
  • Meyn, M. Stephen
  • Murgia, Alessandra
  • Nadeau, Kari C.Y.
  • Neuhausen, Susan L.|||0000-0001-5053-0390
  • Nussbaum, Robert L.|||0000-0003-3445-8880
  • Pirooznia, Mehdi|||0000-0002-4210-6458
  • Potash, James B.
  • Dimster-Denk, Dago F.
  • Rine, Jasper D.
  • Sanford, Jeremy R.
  • Snyder, Michael|||0000-0003-0784-7987
  • Cote, Atina G.
  • Sun, Song
  • Verby, Marta W.
  • Weile, Jochen
  • Roth, Frederick P.
  • Tewhey, Ryan
  • Sabeti, Pardis C.
  • Campagna, Joan
  • Refaat, Marwan M.
  • Wojciak, Julianne
  • Grubb, Soren
  • Schmitt, Nicole
  • Shendure, Jay
  • Spurdle, Amanda B.
  • Stavropoulos, Dimitri J.
  • Walton, Nephi A.
  • Zandi, Peter P.
  • Ziv, Elad
  • Burke, Wylie
  • Chen, Flavia
  • Carr, Lawrence R.
  • Martinez, Selena
  • Paik, Jodi
  • Harris-Wai, Julie
  • Yarborough, Mark|||0000-0001-8188-4968
  • Fullerton, Stephanie M.
  • Koenig, Barbara A.
  • McInnes, Gregory
  • Shigaki, Dustin
  • Chandonia, John-Marc
  • Furutsuki, Mabel
  • Kasak, Laura|||0000-0003-4182-2396
  • Yu, Changhua
  • Chen, Rui
  • Friedberg, Iddo
  • Getz, Gad A.
  • Cong, Qian
  • Kinch, Lisa N.
  • Zhang, Jing
  • Grishin, Nick V.
  • Voskanian, Alin
  • Kann, Maricel G.
  • Tran, Elizabeth
  • Ioannidis, Nilah M.
  • Hunter, Jesse M.
  • Udani, Rupa
  • Cai, Binghuang
  • Morgan, Alexander A.
  • Sokolov, Artem
  • Stuart, Joshua M.|||0000-0002-2171-565X
  • Minervini, Giovanni|||0000-0001-7013-5785
  • Monzon, Alexander M.
  • Batzoglou, Serafim
  • Butte, Atul J.
  • Greenblatt, Marc S.
  • Hart, Reece K.
  • Hernandez, Ryan
  • Hubbard, Tim J.P.
  • Kahn, Scott
  • O'Donnell-Luria, Anne|||0000-0001-6418-9592
  • Ng, Pauline C.
  • Shon, John
  • Veltman, Joris
  • Zook, Justin M.|||0000-0003-2309-8402
Background: The Critical Assessment of Genome Interpretation (CAGI) aims to advance the state-of-the-art for computational prediction of genetic variant impact, particularly where relevant to disease. The five complete editions of the CAGI community experiment comprised 50 challenges, in which participants made blind predictions of phenotypes from genetic data, and these were evaluated by independent assessors. Results: Performance was particularly strong for clinical pathogenic variants, including some difficult-to-diagnose cases, and extends to interpretation of cancer-related variants. Missense variant interpretation methods were able to estimate biochemical effects with increasing accuracy. Assessment of methods for regulatory variants and complex trait disease risk was less definitive and indicates performance potentially suitable for auxiliary use in the clinic. Conclusions: Results show that while current methods are imperfect, they have major utility for research and clinical applications. Emerging methods and increasingly large, robust datasets for training and assessment promise further progress ahead.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Evaluation of the association of heterozygous germline variants in NTHL1 with breast cancer predisposition: an international multi-center study of 47,180 subjects

  • Li, Na
  • Zethoven, Magnus
  • McInerny, Simone
  • Devereux, Lisa
  • Huang, Yu-Kuan
  • Thio, Niko
  • Gutierrez Enriquez, Sara
  • Moles Fernandez, Alejandro
  • Diez Gibert, Orland
Càncer de mama; Genètica del càncer; Mutació, Cáncer de mama; Genética del cáncer; Mutación, Breast cancer; Cancer genetics; Mutation, Bi-allelic loss-of-function (LoF) variants in the base excision repair (BER) gene NTHL1 cause a high-risk hereditary multi-tumor syndrome that includes breast cancer, but the contribution of heterozygous variants to hereditary breast cancer is unknown. An analysis of 4985 women with breast cancer, enriched for familial features, and 4786 cancer-free women revealed significant enrichment for NTHL1 LoF variants. Immunohistochemistry confirmed reduced NTHL1 expression in tumors from heterozygous carriers but the NTHL1 bi-allelic loss characteristic mutational signature (SBS 30) was not present. The analysis was extended to 27,421 breast cancer cases and 19,759 controls from 10 international studies revealing 138 cases and 93 controls with a heterozygous LoF variant (OR 1.06, 95% CI: 0.82–1.39) and 316 cases and 179 controls with a missense variant (OR 1.31, 95% CI: 1.09–1.57). Missense variants selected for deleterious features by a number of in silico bioinformatic prediction tools or located within the endonuclease III functional domain showed a stronger association with breast cancer. Somatic sequencing of breast cancers from carriers indicated that the risk associated with NTHL1 appears to operate through haploinsufficiency, consistent with other described low-penetrance breast cancer genes. Data from this very large international multicenter study suggests that heterozygous pathogenic germline coding variants in NTHL1 may be associated with low- to moderate- increased risk of breast cancer.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Clinical consequences of BRCA2 hypomorphism

  • Castells-Roca, Laia
  • Gutierrez Enriquez, Sara
  • Bonache Real, Sandra
  • Carrasco López, Estela
  • Aza-Carmona, Miriam
  • Montalban Canudas, Gemma
  • Cruz Zambrano, Cristina
  • Llop Guevara, Alba
  • Serra Elizalde, Violeta
  • Diez Gibert, Orland
  • Balmaña Gelpí, Judith
  • Saura Manich, Cristina
  • Bogliolo, Massimo
Breast cancer; Cancer genetics, Cáncer de mama; Genética del cáncer, Càncer de mama; Genètica del càncer, The tumor suppressor FANCD1/BRCA2 is crucial for DNA homologous recombination repair (HRR). BRCA2 biallelic pathogenic variants result in a severe form of Fanconi anemia (FA) syndrome, whereas monoallelic pathogenic variants cause mainly hereditary breast and ovarian cancer predisposition. For decades, the co-occurrence in trans with a clearly pathogenic variant led to assume that the other allele was benign. However, here we show a patient with biallelic BRCA2 (c.1813dup and c.7796 A > G) diagnosed at age 33 with FA after a hypertoxic reaction to chemotherapy during breast cancer treatment. After DNA damage, patient cells displayed intermediate chromosome fragility, reduced survival, cell cycle defects, and significantly decreased RAD51 foci formation. With a newly developed cell-based flow cytometric assay, we measured single BRCA2 allele contributions to HRR, and found that expression of the missense allele in a BRCA2 KO cellular background partially recovered HRR activity. Our data suggest that a hypomorphic BRCA2 allele retaining 37–54% of normal HRR function can prevent FA clinical phenotype, but not the early onset of breast cancer and severe hypersensitivity to chemotherapy.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Role of Splicing Regulatory Elements and In Silico Tools Usage in the Identification of Deep Intronic Splicing Variants in Hereditary Breast/Ovarian Cancer Genes

  • Moles Fernandez, Alejandro
  • Domènech Vivó, Joanna
  • Tenés Felipe, Anna
  • Balmaña Gelpí, Judith
  • Diez Gibert, Orland
  • Gutierrez Enriquez, Sara
Cancer hereditario de mama y ovario; Pseudoexones; Variantes intrónicas profundas spliceogénicas, Càncer hereditari de mama i d'ovari; Pseudoexons; Variants intròniques profundes spliceogèniques, Hereditary breast ovarian cancer; Pseudoexons; Spliceogenic deep intronic variants, The contribution of deep intronic splice-altering variants to hereditary breast and ovarian cancer (HBOC) is unknown. Current computational in silico tools to predict spliceogenic variants leading to pseudoexons have limited efficiency. We assessed the performance of the SpliceAI tool combined with ESRseq scores to identify spliceogenic deep intronic variants by affecting cryptic sites or splicing regulatory elements (SREs) using literature and experimental datasets. Our results with 233 published deep intronic variants showed that SpliceAI, with a 0.05 threshold, predicts spliceogenic deep intronic variants affecting cryptic splice sites, but is less effective in detecting those affecting SREs. Next, we characterized the SRE profiles using ESRseq, showing that pseudoexons are significantly enriched in SRE-enhancers compared to adjacent intronic regions. Although the combination of SpliceAI with ESRseq scores (considering ∆ESRseq and SRE landscape) showed higher sensitivity, the global performance did not improve because of the higher number of false positives. The combination of both tools was tested in a tumor RNA dataset with 207 intronic variants disrupting splicing, showing a sensitivity of 86%. Following the pipeline, five spliceogenic deep intronic variants were experimentally identified from 33 variants in HBOC genes. Overall, our results provide a framework to detect deep intronic variants disrupting splicing., This research was funded by the Spanish Instituto de Salud Carlos III (ISCIII) funding an initiative of the Spanish Ministry of Economy and Innovation, partially supported by European Regional Development FEDER Funds, grant numbers PI16/01218 and PI19/01303. AM-F contract is supported by the award ERAPERMED2019-215 granted by AECC FC and by ISCIII thorough AES 2019, both within the ERAPerMed framework”. J.D.-V. contract is supported by the Secretariat for Universities and Research of the Ministry of Business and Knowledge of the Government of Catalonia and the European Social Fund.